Skip to main content

Advertisement

Table 4 Human recombinant MAO inhibitory profile of eugenol based derivatives

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound/sample IC50 (µM)a hMAO-A IC50 (µM)a hMAO-B Selectivity indexb Docking score hMAO-A Docking score hMAO-B
5a 15.85 ± 0.039 29.37 ± 0.048 0.53 − 9.65 − 3.23
5b 5.989 ± 0.007 31.19 ± 0.016 0.19 − 12.57 − 3.98
7 10.46 ± 0.072 43.31 ± 0.043 0.24 − 11.45 − 1.76
9a 10.84 ± 0.025 47.70 ± 0.073 0.22 − 11.34 − 1.01
9b 16.62 ± 0.004 27.85 ± 0.054 0.59 − 8.99 − 6.45
11 18.06 ± 0.044 26.80 ± 0.077 0.67 − 7.34 − 5.34
13a 38.53 ± 0.018 7.494 ± 0.014 5.14 − 2.45 − 11.87
13b 52.55 ± 0.038 9.183 ± 0.034 5.72 − 1.09 − 10.45
13c 22.38 ± 0.067 12.66 ± 0.021 1.76 − 6.45 − 10.32
13d 20.89 ± 0.023 13.95 ± 0.005 1.49 − 5.32 − 9.99
16 7.348 ± 0.027 49.15 ± 0.011 0.14 − 11.98 − 2.21
17 13.92 ± 0.051 34.20 ± 0.037 0.40 − 9.99 − 4.23
Eugenol 16.54 ± 0.045 13.30 ± 0.037 1.24 − 6.46 − 7.82
Pargyline 20.04 ± 0.095 − 6.061
Chlorgyline 18.74 ± 0.096 − 5.773
  1. aValues related for the evaluated compound absorption which provide 50% inhibition of MAO-A and MAO-B, action, and are the mean SEM; statistical significance: p < 0.05 against the equivalent IC50 values achieved against MAO-A and MAO-B, as identified through ANOVA/Dunnett’s test
  2. bSelectivity index = IC50 (MAO-A)/IC50 (MAO-B)